Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.59 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.47 |
| ▸ | PDE4A | P27815 | 6/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GGT1 | P19440 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1815276 | 1.00 | KAT2B (0.59) | KAT2BBAZ2BPDE4DPDE4APDE4B | |
| SCHEMBL8890812 | 0.91 | KAT2B (0.71) | KAT2BBAZ2BPDE4DGRIK1GRIA2 | |
| SCHEMBL31056850 | 0.87 | KAT2B (0.50) | KAT2BBAZ2BGRIK1GRIA2EPHX2 | |
| SCHEMBL3441348 | 0.87 | KAT2B (0.58) | KAT2BBAZ2BPDE4DPDE4APDE4B | |
| SCHEMBL1811109 | 0.84 | KAT2B (0.63) | KAT2BBAZ2BPDE4DPDE4APDE4B | |
| SCHEMBL2354090 | 0.84 | KAT2B (0.56) | KAT2BBAZ2BPDE4DPDE4APDE4B | |
| SCHEMBL1811110 | 0.84 | KAT2B (0.63) | KAT2BBAZ2BPDE4DPDE4APDE4B | |
| SCHEMBL20561976 | 0.82 | EPHX2 (0.58) | KAT2BBAZ2BGRIK1GRIA2EPHX2 | |
| SCHEMBL29993812 | 0.82 | KAT2B (0.53) | KAT2BBAZ2BPDE4DPDE4APDE4B | |
| SCHEMBL1672509 | 0.80 | PDE4D (0.46) | KAT2BBAZ2BPDE4DPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011061590-A1 | NOVEL CARBOXAMIDE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2011-05-26 | — | — | WO | disclosed |
| US-7442704-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2008-10-28 | — | — | US | disclosed |
| EP-1891058-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| US-7332483-B2 | 3-(5-benzamido-2-chlorophenyl)-7-methoxy-3,4-dihydroquinazolin-4-one;cytokines (tumor necrosis factor and interleukins) inhibitor; antiinflammatory agent, rheumatoid arthritis, osteoarthritis, psoriasis, chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-20060281734-A1 | Amide derivatives | BROWN DEARG S | 2006-12-14 | — | — | US | disclosed |
| WO-2006125972-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
| US-7008945-B1 | Amide derivatives | ASTRAZENECA AB (SE) | 2006-03-07 | — | — | US | disclosed |
| US-20050245551-A1 | Amide derivatives | ASTRAZENECA AB | 2005-11-03 | — | — | US | disclosed |
| EP-1163237-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000055153-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245551-A1 | Amide derivatives | IL6, IL6ST, IL1B | KAT2B 1124/4885BAZ2B 2158/4885PDE4D 3929/4885 |
| US-20060281734-A1 | Amide derivatives | IL6, IL6ST, IL1B | KAT2B 1124/4885BAZ2B 2158/4885PDE4D 3929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.